Table 4.
Trial outcomes in Routine F/U and Home F/U patients
| CARDIAC AND NEUROLOGIC MORBIDITY AND MORTALITY (N=248) | P | # OF COMPLICATIONS | ||
|---|---|---|---|---|
|
Low MAP (n=124) |
12.9% |
|
Perioperative |
13 |
| |
6 months |
4 |
||
| |
Total |
17 |
||
| |
0.026 |
|
||
|
High MAP (n=124) |
4.8% |
|
Perioperative |
4 |
| |
|
6 months |
4 |
|
| |
|
Total |
6 |
|
|
Total Cardiac and neurologic morbidity and mortality |
8.9% |
|
Total |
22 |
|
Neurocognitive Dysfunction at 6 months (n=225) | ||||
| Low MAP |
12.4% |
0.86 |
6 months |
14 |
| High MAP |
11.6% |
|
6 months |
13 |
|
Total |
12.0% |
|
|
27 |
|
Functional Decline at 6 months (n=217) | ||||
| Low MAP |
8.3% |
0.62 |
6 months |
9 |
| High MAP |
6.5% |
|
6 months |
7 |
|
Total |
7.4% |
|
|
16 |
|
Combined Trial Outcome (n=248) | ||||
| Low MAP |
27.4% |
0.032 |
|
34 |
| High MAP |
16.1% |
|
|
20 |
| Total | 21.8% | 54 | ||
(Surveillance on 248 participants perioperatively and 237 participants at 6 months).
MAP= Mean Arterial Pressure. Combined Trial Outcomes included the following complications at 6 months: cardiac morbidity (myocardial infarction, pulmonary edema, adult respiratory distress syndrome and cardiogenic shock); neurologic morbidity (major focal deficit); all-cause mortality; functional decline (>5 point decline in physical component summary measure of the SF-36); and neurocognitive deterioration (within-patient differences on an 11 test neurocognitive battery).